Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.

Autor: Haydu JE; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Maron JS; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA., Redd RA; Department of Data Sciences, Dana-Farber Cancer Institute, Boston, MA., Gallagher KME; Immune Monitoring Laboratory, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA; and., Fischinger S; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA., Barnes JA; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Hochberg EP; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Johnson PC; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Takvorian RW; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Katsis K; Immune Monitoring Laboratory, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA; and., Portman D; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Ruiters J; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Sechio S; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Devlin M; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Regan C; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Blumenthal KG; Department of Allergy and Immunology., Banerji A; Department of Allergy and Immunology., Judd AD; Department of Allergy and Immunology., Scorsune KJ; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., McGree BM; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Sherburne MM; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Lynch JM; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Weitzman JI; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Lei M; Department of Pharmacy., Kotton CN; Department of Infectious Diseases, and., Dighe AS; Department of Pathology, Massachusetts General Hospital, Boston, MA., Maus MV; Immune Monitoring Laboratory, Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA; and., Alter G; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, MA., Abramson JS; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA., Soumerai JD; Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA.

Publikováno v: Blood advances [Blood Adv] 2022 Mar 22; Vol. 6 (6), pp. 1671-1683.